XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue from Contracts with Customers (Tables)
3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes revenue by revenue source as follows:
Three Months Ended
March 31,
Major Products/Service Lines (in thousands)20232022
    Product revenue, net(1)
$292,256 $180,009 
    License and royalty revenues(2)
8,528 28,871 
Total revenues$300,784 $208,880 
________________________________
(1)The Company’s product revenue includes PYLARIFY and DEFINITY among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.
(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG.
Revenue by product category on a net basis is as follows:
Three Months Ended
March 31,
(in thousands)20232022
   PYLARIFY195,470 92,777 
   Other radiopharmaceutical oncology717 1,327 
Total radiopharmaceutical oncology196,187 94,104 
   DEFINITY$68,824 $58,328 
   TechneLite20,986 22,605 
   Other precision diagnostics5,807 5,265 
Total precision diagnostics95,617 86,198 
Strategic partnerships and other revenue8,980 28,578 
Total revenues$300,784 $208,880